Results 211 to 220 of about 52,658 (264)

Repurposing piroxicam for antithrombotic and cardiopulmonary protection: Pharmacological rationale and therapeutic potential.

Indian J Pharmacol
Khalid W, Khan AU.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Thienopyrimidine-based P2Y12 platelet aggregation inhibitors

Bioorganic and Medicinal Chemistry Letters, 2009
Herein we describe the design and synthesis of a novel series of potent thienopyrimidine P2Y12 inhibitors and the negative impact protein binding has on the inhibition of platelet aggregation.
Steven W, Kortum, Rhonda M, Lachance, Barbara A, Schweitzer, Gopichand, Yalamanchili, Hayat, Rahman, Michael D, Ennis, Rita M, Huff, Ruth E, TenBrink   +7 more
exaly   +3 more sources

Disposition of anagrelide, an inhibitor of platelet aggregation

Clinical Pharmacology and Therapeutics, 1981
A single dose of 14C-anagrelide (6,7-dichloro-1,5-dihydroimidazo [2,1-b] quinazoline-2(3H)-one monohydrochloride) equivalent to 1 mg free base and containing 100 muCi radioactivity, was taken by five healthy, fasting men. Blood, plasma, urine, and feces were analyzed for total radioactivity. Plasma and urine concentrations of anagrelide were determined,
R C, Gaver, G, Deeb, K A, Pittman, R D, Smyth   +3 more
openaire   +2 more sources

Prostaglandins as Inhibitors of Human Platelet Aggregation

British Journal of Haematology, 1979
Summary. The potencies of prostaglandins (PG) I2, PGD2 and PGE1 as inhibitors of human platelet aggregation induced by threshold concentrations of four aggregating agents were determined in platelet‐rich plasma from normal individuals who had not ingested aspirin. The order of activity against ADP, adrenaline and collagen was always PGI2 > PGD2 >
DI MINNO, GIOVANNI, Silver MJ, de Gaetano G.   +2 more
openaire   +3 more sources

Platelet aggregation inhibitors in neurology

Pharmacy World & Science, 1993
This literature review reports on secondary prevention of ischaemic stroke. The aim of secondary prevention is to protect patients who belong to a risk group from the occurrence of brain infarction. Symptomatic patients with a demonstrated carotid artery stenosis of 70% and more will most probably benefit from carotid endarterectomy if performed by a ...
openaire   +2 more sources

Hypopigmentation in Dogs Treated with an Inhibitor of Platelet Aggregation

Toxicologic Pathology, 1989
Hypopigmentation was the principal manifestation of systemic toxicity when the experimental platelet aggregation inhibitor, PD-89454, was orally administered to Beagle dogs for 28 days. Pigmentation changes were present in skin of nose, lips and eyelids and mucosa of hard palate.
K M, Walsh, A W, Gough
openaire   +2 more sources

Inhibitors of “spontaneous” platelet aggregation in whole blood

Atherosclerosis, 1985
In vitro 'spontaneous' platelet aggregation has been studied in whole blood. The spectrum of activity of materials known to influence platelet aggregation in platelet-rich plasma proved different in whole blood. Thus dipyridamole and one of its analogues SH1242 had a striking effect in whole blood whilst aspirin, chlorpromazine and K3920 had little or ...
M J, Harrison, S S, Pollock, M, Steiner, E, Weisblatt   +3 more
openaire   +2 more sources

New pyridazinone derivatives as inhibitors of platelet aggregation

European Journal of Medicinal Chemistry, 1995
Summary The synthesis and evaluation of the biological activity of a series of 3(2 H )-pyridazinone derivatives is reported. We assessed the in vitro activity of these compounds on aggregation and production of thromboxane A 2 and prostaglandin E 2 of human platelets.
S. Corsano, R. Vezza, R. Scapicchi, S. Foresi, G. Strappaghetti, NENCI, Giuseppe Giorgio, GRESELE, Paolo   +6 more
openaire   +2 more sources

In Vitro Evaluation of Inhibitors of Platelet Release and Aggregation

Archives of Surgery, 1975
In order to determine which drugs would be most effective as inhibitors of platelet release and aggregation, in vitro release reactions and platelet aggregometry were used to evaluate aspirin, dipyridamole, sulfinpyrazone, flurbiprofen, low molecular weight dextran (dextran 40), prostaglandin E1 (PGE1), apyrase, and adenosine.
J C, Rosenberg, T L, Sell
openaire   +2 more sources

Lebetin Peptides: Potent Platelet Aggregation Inhibitors

Pathophysiology of Haemostasis and Thrombosis, 2001
Lebetins from <i>Macrovipera lebetina</i> snake venom constitute a new class of inhibitors of platelet aggregation. There are two groups of peptides: lebetin 1 (L1; 11- to 13-mer) and lebetin 2 (L2; 37- to 38-mer). The short lebetins are identical to the N-terminal segments of the longer ones.
N, Marrakchi, K, Mabrouk, I, Regaya, S, Sarray, M, Fathallah, H, Rochat, M, El Ayeb   +6 more
openaire   +2 more sources